Trisalus Life Sciences (TLSI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
31 Mar, 2026Voting matters and shareholder proposals
Election of two director nominees, Mary Szela and Gary Gordon, to serve until the 2029 Annual Meeting or until earlier departure.
Ratification of Grant Thornton LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote on the frequency of future stockholder advisory votes on executive compensation, with a recommendation for every three years.
Advisory vote on the compensation of named executive officers.
Provision for other business to be addressed as may properly come before the meeting or any adjournment.
Board of directors and corporate governance
Two nominees, Mary Szela and Gary Gordon, are recommended for election to the board.
Audit committee and external auditor matters
Grant Thornton LLP is recommended for ratification as the independent registered public accounting firm for the upcoming fiscal year.
Latest events from Trisalus Life Sciences
- Proxy covers director elections, auditor ratification, and executive compensation votes.TLSI
Proxy filing31 Mar 2026 - Strong revenue growth, expanded product suite, and robust 2026 outlook with $46M new capital.TLSI
Q4 20255 Mar 2026 - Q2 revenue up 60% to $7.4M, gross margin at 88%, net loss narrowed to $4.3M.TLSI
Q2 20241 Feb 2026 - Rapid growth in drug delivery tech, new clinical data, and EBITDA positive targeted for 2025.TLSI
Maxim Group’s 2024 Healthcare Virtual Summit19 Jan 2026 - Q3 revenue up 42% year-over-year; 2025 outlook targets 50%+ growth and positive EBITDA.TLSI
Q3 202414 Jan 2026 - 2024 revenue up 59% to $29.4M; 2025 outlook targets 50%+ growth and positive EBITDA.TLSI
Q4 202426 Dec 2025 - Resale of 10.6M shares by holders may impact stock volatility; no proceeds to the company.TLSI
Registration Filing16 Dec 2025 - Registration allows OrbiMed to resell 91,263 warrant shares; no resale proceeds to the company.TLSI
Registration Filing16 Dec 2025 - $22M private placement shares registered for resale; no proceeds to company; oncology focus.TLSI
Registration Filing16 Dec 2025